Original article | published - printed | peer reviewed | Open Access
Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.
Frontiers in Immunology
2023 / June
;
14:
1160148 -
Bibliometric indicators
Impact Factor = 5.7
Citations (WOS) = 17
DOI = 10.3389/fimmu.2023.1160148
PubMed-ID = 37342352
Authors
Nolde M*, Alayash Z, Reckelkamm S, Kocher T1, Ehmke B, Holtfreter B1, Baurecht H, Georgakis M, Baumeister SE
Affiliations
Abstract
Interleukin 6 (IL-6) is considered to play a role in the dysbiotic host response in the development of periodontitis. While the inhibition of the IL-6 receptor using monoclonal antibodies is a well-established therapy for some diseases, so far, its potential benefit in patients with periodontitis has not been examined. We tested the association of genetically proxied downregulation of IL-6 signaling with periodontitis to explore whether downregulation of IL-6 signaling could represent a viable treatment target for periodontitis.
Published in
Frontiers in Immunology
| Year | 2023 |
| Month/Hj | June |
| Impact Factor (2023) | 5.7 |
| Volume | 14 |
| Issue | |
| Pages | 1160148 - |
| Open Access | ja |
| Peer reviewed | ja |
| Article type | Original article |
| Article state | published - printed |
| DOI | 10.3389/fimmu.2023.1160148 |
| PubMed-ID | 37342352 |
Common journal data
Short name: FRONT IMMUNOL
ISSN: 1664-3224
eISSN: 1664-3224
Country: SWITZERLAND
Language: English
Categories:
Impact factor trend
ISSN: 1664-3224
eISSN: 1664-3224
Country: SWITZERLAND
Language: English
Categories:
- IMMUNOLOGY
Impact factor trend
| Year | Impact Factor |
|---|---|
| 2015 | 5.695 |
| 2016 | 6.429 |
| 2017 | 5.511 |
| 2018 | 4.716 |
| 2019 | 5.085 |
| 2020 | 7.561 |
| 2021 | 8.786 |
| 2022 | 7.3 |
| 2023 | 5.7 |
| 2024 | 5.9 |